Related Experiment Videos
[Pregnancy and hematologic malignancies: a therapeutic approach]
A Delmer1, F Bauduer, F Ajchenbaum-Cymbalista
1Service d'hématologie, Hôtel-Dieu, Paris, France.
Bulletin Du Cancer
|April 1, 1994
Summary
Managing cancer during pregnancy is complex. For malignant blood diseases, treatment decisions require careful evaluation of risks to mother and fetus, with outcomes often favorable after the second trimester.
Area of Science:
- Hematology
- Oncology
- Maternal-Fetal Medicine
Context:
- Pregnancy coexisting with malignant blood diseases presents a therapeutic challenge.
- Cytostatic agents pose potential risks to both the mother and the developing fetus.
- Management requires a multidisciplinary approach considering disease prognosis and gestational term.
Purpose:
- To outline the therapeutic considerations for managing malignant blood diseases during pregnancy.
- To evaluate the risks and benefits of treatment modalities, including cytostatic agents and radiation therapy.
- To provide guidance on decision-making regarding therapeutic abortion.
Summary:
- Malignant blood diseases (Hodgkin's disease, leukemia, lymphoma, myeloproliferative disorders) during pregnancy necessitate careful risk-benefit assessment for treatment.
- Therapeutic abortion is considered only after evaluating treatment urgency, disease prognosis, gestational stage, fetal/maternal risks, and psychosocial factors.
- Post-second trimester, teratogenicity of cytostatic drugs appears minimal, and pregnancy outcomes are often favorable regardless of the specific hemopathy. Radiation therapy requires extreme caution, limited to supradiaphragmatic areas.
Impact:
- Informs clinical decision-making for a rare but critical patient population.
- Highlights the potential for favorable pregnancy outcomes with appropriate management strategies.
- Emphasizes the need for individualized treatment plans in complex obstetric-oncologic cases.